Eli Lilly (LLY)

These companies may perform well in any market environment.

The global AI training dataset market was valued at USD 3.2 billion in 2025 and is projected to reach USD 16.3 billion by 2033, expanding from USD 3.9 bill

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Ch...

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.

FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own.

Ahead of Q4 2026, analysts favor Western Digital, NVIDIA, Vertiv, Eli Lilly, and JPMorgan Chase as steady, best-in-class stocks offering growth with less volatility for buy-and-hold investors.

The company is still looking to bounce back after the beating it took in recent years.

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

The drugmaker has a lot riding on continued clinical progress.

Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.

These stocks have been struggling lately, but they could be underrated buys in the long run.

Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company’s executive vice president and president of Lilly USA and G

The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those.

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

XLV's 0.08% expense ratio and 22.7% 1-year return outpace IXJ's global reach, but international diversification comes at a cost.

Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.

XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.

The worst may be in the rearview mirror for the drugmaker.

AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.

Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.

During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average.

Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.